These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1080 related items for PubMed ID: 16442246

  • 1. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):81-9. PubMed ID: 16442246
    [Abstract] [Full Text] [Related]

  • 2. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):72-80. PubMed ID: 16442248
    [Abstract] [Full Text] [Related]

  • 3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM, MacRitchie HB, Marriott C, Martin GP.
    Int J Pharm; 2007 Mar 21; 333(1-2):45-55. PubMed ID: 17064863
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.
    de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW.
    Pharmazie; 2004 Sep 21; 59(9):692-9. PubMed ID: 15497751
    [Abstract] [Full Text] [Related]

  • 5. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.
    de Boer AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman HG, Frijlink HW.
    Eur J Pharm Sci; 2006 Jun 21; 28(3):171-8. PubMed ID: 16650739
    [Abstract] [Full Text] [Related]

  • 6. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS, Lau R.
    Int J Pharm; 2010 Feb 15; 386(1-2):6-14. PubMed ID: 19922775
    [Abstract] [Full Text] [Related]

  • 7. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H, Markefka P, teWierik H, Kammelar R.
    Int J Pharm; 2006 Feb 17; 309(1-2):51-9. PubMed ID: 16377105
    [Abstract] [Full Text] [Related]

  • 8. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD, Santo JG, Yakub B, Dennison M, Master H, Buckton G.
    Int J Pharm; 2010 May 31; 391(1-2):137-47. PubMed ID: 20211715
    [Abstract] [Full Text] [Related]

  • 9. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 31; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 10. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M, Kappl M, Butt HJ, Urbanetz NA, Lippold BC.
    Eur J Pharm Biopharm; 2007 Sep 31; 67(2):579-86. PubMed ID: 17418548
    [Abstract] [Full Text] [Related]

  • 11. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ, Smyth HD.
    Int J Pharm; 2010 Dec 15; 402(1-2):1-9. PubMed ID: 20816928
    [Abstract] [Full Text] [Related]

  • 12. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U, Marschall K, Fyrnys B, Wedel M.
    Curr Med Res Opin; 2005 Jun 15; 21(6):827-33. PubMed ID: 15969882
    [Abstract] [Full Text] [Related]

  • 13. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W, Alhalaweh A, Velaga SP, Nokhodchi A.
    Int J Pharm; 2011 Dec 12; 421(1):12-23. PubMed ID: 21945739
    [Abstract] [Full Text] [Related]

  • 14. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.
    Dickhoff BH, de Boer AH, Lambregts D, Frijlink HW.
    Int J Pharm; 2006 Dec 11; 327(1-2):17-25. PubMed ID: 16920287
    [Abstract] [Full Text] [Related]

  • 15. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W, Martin GP, Ticehurst MD, Momin MN, Nokhodchi A.
    Int J Pharm; 2010 Jun 15; 392(1-2):178-88. PubMed ID: 20363301
    [Abstract] [Full Text] [Related]

  • 16. Novolizer: how does it fit into inhalation therapy?
    Magnussen H.
    Curr Med Res Opin; 2005 Jun 15; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
    [Abstract] [Full Text] [Related]

  • 17. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
    Raula J, Lähde A, Kauppinen EI.
    Int J Pharm; 2009 Jan 05; 365(1-2):18-25. PubMed ID: 18789380
    [Abstract] [Full Text] [Related]

  • 18. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA, Shur J, Ruecroft G, Hipkiss D, Price R.
    Int J Pharm; 2012 Jul 01; 430(1-2):26-33. PubMed ID: 22449413
    [Abstract] [Full Text] [Related]

  • 19. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN, Bierend H, Robins E, Steckel H, Flament MP.
    Int J Pharm; 2012 Jan 17; 422(1-2):75-82. PubMed ID: 22036653
    [Abstract] [Full Text] [Related]

  • 20. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W, Martin GP, Larhrib H, Ticehurst MD, Kolosionek E, Nokhodchi A.
    Colloids Surf B Biointerfaces; 2012 Jan 01; 89():29-39. PubMed ID: 21962946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.